Kathrin Blagec

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson et al. · The Lancet · 2023 · 462 citations · Full text

Drug Safety, Adverse Drug Reactions, Pharmacoepidemiology +9

Implementing pharmacogenomics decision support across seven European countries: The Ubiquitous Pharmacogenomics (U-PGx) project

Kathrin Blagec, Rudolf Koopmann, Mandy Crommentuijn – van Rhenen et al. · Journal of the American Medical Informatics Association · 2018 · 94 citations · Full text

Ubiquitous Pgx, Ubiquitous Pharmacogenomics, Translational Medicine +23

Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available

Matthias Samwald, Hong Xu, Kathrin Blagec et al. · PLoS ONE · 2016 · 81 citations · Full text

Mapping global dynamics of benchmark creation and saturation in artificial intelligence

Simon Ott, Adriano Barbosa-Silva, Kathrin Blagec et al. · Nature Communications · 2022 · 59 citations · Full text

A curated, ontology-based, large-scale knowledge graph of artificial intelligence tasks and benchmarks

Kathrin Blagec, Adriano Barbosa-Silva, Simon Ott et al. · Scientific Data · 2022 · 48 citations · Full text